(Reuters) -Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine. The U.S. Court of Appeals for the Federal Circuit said that the last remaining J&J patent covering its Invega Sustenna may be invalid, sending the case back for a New Jersey federal court to reconsider. A J&J spokesperson said the company will "continue defending the intellectual property of Invega Sustenna."
By Sabela Ojea Viatris has signed a transaction agreement with Cooper Consumer Health, according to a Securities and Exchange Commission filing on Tuesday..
India Business News: Biocon Biologics, a subsidiary of Biocon has signed a distribution agreement with Sandoz, granting the company exclusive rights to promote, sell and d
By Josh Beckerman Theravance Biopharma reached a cooperation agreement with stockholder Irenic Capital Management, which in February criticized the company's.